Rapid Assessment of Nanoparticle Extravasation in a Microfluidic Tumor Model
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index; 18 of the 37 sources its claims cite were checked for support.
Abstract
High Resolution Image Download MS PowerPoint Slide The development of nanoparticle-based targeted therapeutics for the treatment of cancer requires a well-defined understanding of the tumor microenvironment, which is challenging due to tumor complexity and heterogeneity. Recent advancements in three-dimensional (3D) cell models such as tumor-on-a-chip devices can overcome some of these challenges by providing coculture in vitro systems (tumor surrounded by tubular endothelial cells) that mimic native cellular environments to accurately study the enhanced permeability and retention (EPR) potential of drug delivery systems under flow conditions. However, inducing “leaky” vasculature in endothelial cells surrounding solid tumors in microfluidic devices is not readily controllable and highly dependent on tumor cell identity. Utilizing a microfluidic tumor model (MTM) consisting of a tumor region surrounded by a 3D microvascular network, we have simulated the EPR effect by activating a known regulator of endothelial junction formation and edema: the transient receptor potential vanilloid 4 (TRPV4) ion channel, to rapidly assess extravasation and tumor accumulation of nanoparticles of different sizes and surface chemistries. Treatment with a selective TRPV4 agonist stimulated reorganization of the actin cytoskeleton and disruption of adherens junctions to provide a concentration-dependent or “tunable” leakiness, confirmed by increased tumor uptake of fluorescent dextran macromolecular tracers from the vascular channels. Although this controlled 3D in vitro vascular-edema system may not exemplify all of the complexities of edema mechanisms in vivo, it provides a rapid, materials-focused screening method to assess the extravasation and tumor uptake potential of nanoparticles with distinct properties. We show that the passage of nanoparticles through leaky vasculature is not solely governed by particle size but also by surface chemistry, where surface tertiary amines limit tumor cell association due to unwanted endothelial interactions.
Overview
CoChat Summary
## TL;DR
This paper presents a microfluidic tumor-on-a-chip model in which TRPV4 activation was used to tune endothelial leakiness and rapidly screen nanoparticle extravasation into tumors. In this system, 40 nm carboxylated nanoparticles showed the greatest tumor penetration, and surface chemistry also affected endothelial association, with tertiary amines increasing endothelial interactions.
## Key findings
- The vascularized microfluidic tumor model had a tumor compartment separated from a branched endothelial network by a 2 μm porous interface.
- TRPV4 agonist GSK101 increased endothelial leakiness in a concentration-dependent way: 1, 3, and 10 nM reduced VE-cadherin detection, increased endothelial gaps, and altered F-actin organization.
- In the dextran assay, nonstimulated conditions gave 22.15% fluorescence distribution for FD4 (4 kDa) and 6.22% for RD70 (70 kDa) in the tumor area; with GSK101, uptake increased, with 3 nM considered permissive for 70 kDa macromolecule passage.
- For nanoparticles, 40 nm carboxylic acid particles had the greatest tumor penetration and endothelial/tumor cell association, and 70 nm tertiary amine particles associated more strongly with HUVECs than 70 nm carboxylic acid particles.
- With 3 nM GSK101, nanoparticle extravasation into the tumor increased for all three sizes tested, with a significant increase in MDA-MB-231 cell association and no effect on HUVEC association; the paper also reports 2-fold higher FD4 and 3-fold higher RD70 extravasation.
## Methods
- The study used a SynVivo microfluidic tumor model with MDA-MB-231 breast cancer cells in the tumor compartment and HUVECs in a surrounding 3D vascular network under continuous flow.
- Endothelial barrier leakiness was induced with the TRPV4 agonist GSK1016790A at 1, 3, or 10 nM, and permeability was assessed using FITC-dextran 4 kDa and rhodamine dextran 70 kDa.
- Nanoparticle screening used Cy5-labeled polymer nanoparticles of approximately 40, 70, and 130 nm, plus 70 nm particles with carboxylic acid or tertiary amine surface groups; analysis combined confocal microscopy and flow cytometry.
## Limitations
- The paper states that the model “could not fully represent the complexity of biological systems”, specifically noting the lack of plasma proteins and circulating blood cells that affect nanoparticle properties and nanobio interactions.
- The authors note that HUVECs may not entirely recapitulate all known roles for TRPV4 in tumor vasculature.
- They also say the use of variable flow rates and comparisons with straight-channel devices remain only a theoretical advantage until more rigorous analyses are done.
- Evident from the text: the work is a proof-of-concept in vitro study, so its findings are not direct in vivo validation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Valid · 1 Not valid · 4 Not checked · 47 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“most likely through Ca 2+ -dependent processes, 35”
What the sources say
- Disputedcites [35] Fiorio Pla, 2012, TRPV4Mediates Tumor-Derived Endothelial Cell Migration Via Arachidonic Acid-Activated Actin Remodeling, Oncogene sourceExperimental — accuracy not yet measured
The Results section on AA-induced Ca2+ responses places actin remodeling upstream of the TRPV4-mediated Ca2+ response, rather than describing F-actin rearrangement as Ca2+-dependent. The Results section on actin remodeling also reports that activating TRPV4 with 4αPDD does not affect actin. Our copy provides no page numbers for these passages. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A vascularized MTM has been developed and characterized, consisting of a tumor compartment and a surrounding network of vessels, separated by a 2 μ m wide porous interface (Figure 1A,B). 17,21,26”
What the sources say
- Supportedcites [17] Prabhakarpandian, 2015, Synthetic TumorNetworks for Screening Drug Delivery Systems, J. Controlled Release source
The Design of Synthetic Tumor Network section describes a tumor-growth region adjacent to a microvascular network, with engineered 2 µm leaky gaps between them. The Fabrication and Testing results describe the vascular channel, barrier, and tumor chamber and report that the 2 µm leaky vasculature was functional. (LLM, conf=0.93)
- Supportedcites [21] Tang, 2017, A Biomimetic Microfluidic Tumor Microenvironment Platform Mimicking the EPR Effect for Rapid Screening of Drug Delivery Systems, Sci. Rep. source
The Results section describes vascular and tumor compartments separated by a porous micro-pillar interface. Materials and Methods (Microfabrication of the bMTM) specifies that the compartments communicate through 2 µm pores; the 2 µm measurement describes the pores, rather than the overall width of the interface. The supplied passages have no page numbers. (LLM, conf=0.89)
- Partly supportedcites [26] Prabhakarpandian, 2008, Synthetic Microvascular Networks for Quantitative Analysis of Particle Adhesion, Biomed. Microdevices sourceExperimental — accuracy not yet measured
The Introduction describes a microfluidic network of vessels developed to study particle adhesion, and Results §3.1 reports its fabrication and perfusion. The cited paper does not describe a tumor compartment or a 2 μm porous interface; Methods §2.2 instead describes a semicircular network sealed to glass. No page numbers are available in our copy. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HUVECs may not entirely recapitulate all known roles for TRPV4 in tumor vasculature. 24,28,35,51,53,66”
What the sources say
- Not checked — no full text of the sourcecites [24] Willette, 2008, Systemic Activation of the Transient Receptor Potential Vanilloid Subtype 4 Channel Causes Endothelial Failure and Circulatory Collapse: Part 2, J. Pharmacol. Exp. Ther. source
- Not checked — no full text of the sourcecites [28] Thorneloe, 2012, An Orally Active TRPV4 Channel Blocker Prevents and Resolves Pulmonary Edema Induced by Heart Failure, Sci. Transl. Med. source
- Partly supportedcites [35] Fiorio Pla, 2012, TRPV4Mediates Tumor-Derived Endothelial Cell Migration Via Arachidonic Acid-Activated Actin Remodeling, Oncogene sourceExperimental — accuracy not yet measured
The Results section reports higher TRPV4 expression and responses in tumor-derived endothelial cells than in the normal microvascular endothelial cells tested, supporting the caution that a normal-cell model may not capture tumor-vascular TRPV4 biology. The paper does not directly compare HUVECs with tumor-derived endothelial cells, so the HUVEC-specific part remains untested (page not provided in our copy). (LLM, conf=0.82)
- Partly supportedcites [51] Thoppil, 2015, TRPV4 Channel Activation Selectively Inhibits Tumor Endothelial Cell Proliferation, Sci. Rep. sourceExperimental — accuracy not yet measured
The Results (page unavailable) report that tumor endothelial cells proliferated more than normal endothelial cells and that TRPV4 activation did not affect normal endothelial-cell proliferation. This supports the caution that normal endothelial cells may not capture TRPV4's roles in tumor vasculature, but the study did not examine HUVECs specifically or establish the full range of those roles. (LLM, conf=0.83)
- Could not verifycites [53] Huh, 2012, A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice, Sci. Transl. Med. sourceExperimental — accuracy not yet measured
The Results (‘Drug testing on-chip’; page unavailable) discuss TRPV4-mediated vascular leakage in a lung model, and the Methods (‘Microfluidic cell culture’; page unavailable) identify the cells as human pulmonary microvascular endothelial cells. Searches for HUVECs and tumor vasculature found no passage addressing whether HUVECs recapitulate TRPV4’s roles in tumor vessels. (LLM, conf=0.76)
- Partly supportedcites [66] Adapala, 2016, Activation of Mechanosensitive Ion Channel TRPV4 Normalizes Tumor Vasculature and Improves Cancer Therapy, Oncogene sourceExperimental — accuracy not yet measured
The Results section on tumor endothelial cells reports lower TRPV4 expression in tumor-derived cells than in normal endothelial cells, and the mouse tumor results link TRPV4 loss to abnormal tumor vessels (page unavailable in our copy). These findings support the concern that normal endothelial cells may not capture every tumor-vascular role of TRPV4, but the paper does not study HUVECs or assess their suitability as a model. (LLM, conf=0.78)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Evidence suggests TRPV4 expression levels are higher in tumor-associated ECs (TECs) relative to normal ECs 35”
What the sources say
- Supportedcites [35] Fiorio Pla, 2012, TRPV4Mediates Tumor-Derived Endothelial Cell Migration Via Arachidonic Acid-Activated Actin Remodeling, Oncogene source
The Results section, under “Tumor-derived endothelial cells display high expression and function of TRPV4” (passage 1; page not provided), reports markedly higher TRPV4 expression in breast tumor-derived ECs than in normal microvascular ECs, and higher expression in renal tumor-derived ECs than in normal glomerular ECs. It concludes that endogenous TRPV4 expression is significantly increased in TECs compared with normal ECs. (LLM, conf=0.94)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“30 min pretreatment with GSK101 signi fi cantly increased dye uptake into the tumor area over the subsequent 90 min period, in a GSK101 concentration-dependent manner, providing the fi rst indication of the relationship between TRPV4 activity and the extravasation potential of di ff erently sized macromolecules (Figure 3A,B).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
24 more claims
Create a free account to see all 61 claims and to verify the 6 references still open.
- Probably not a substantial claim. 9
- It may state two separate claims as one. 26
- The quote only partly states this claim. 1
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
The present and future role of microfluidics in biomedical research
Sackmann, E. K., Fulton, A. L., & Beebe, D. J. (2014) · Nature · doi:10.1038/nature13118 · Cited by 2,995
He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF
Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., & Connolly, D. T. (1989) · Science · doi:10.1126/science.2479987 · Cited by 2,061
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Three-dimensional cell culture: the missing link in drug discovery
Breslin, S., & O’Driscoll, L. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.003 · Cited by 1,332
Endothelial cell–cell junctions: happy together
Dejana, E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1357 · Cited by 1,188
A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice
Huh, D., Leslie, D. C., Matthews, B. D., Fraser, J. P., Jurek, S., Hamilton, G. A., Thorneloe, K. S., McAlexander, M. A., & Ingber, D. E. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004249 · Cited by 993
VE-Cadherin and Endothelial Adherens Junctions: Active Guardians of Vascular Integrity
Giannotta, M., Trani, M., & Dejana, E. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.08.020 · Cited by 854
Dvorak, H. F., Nagy, J. A., Dvorák, J., & Dvořàk, A. M. (1988) · PubMed Central · Cited by 679
A Decade of the Protein Corona
Ke, P. C., Lin, S., Parak, W. J., Davis, T. P., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b08008 · Cited by 672
Self-citationThe importance of nanoparticle shape in cancer drug delivery
Truong, N. P., Whittaker, M. R., Mak, C. W., & Davis, T. P. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.950564 · Cited by 594
Self-citationImpact of the physical microenvironment on tumor progression and metastasis
Spill, F., Reynolds, D. S., Kamm, R. D., & Zaman, M. H. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.02.007 · Cited by 581
Tuning payload delivery in tumour cylindroids using gold nanoparticles
Kim, B., Han, G., Toley, B. J., Kim, C.-K., Rotello, V. M., & Forbes, N. S. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2010.58 · Cited by 479
3D microtumors in vitro supported by perfused vascular networks
Sobrino, A., Phan, D. T. T., Datta, R., Wang, X., Hachey, S. J., Romero-López, M., Gratton, E., Lee, A. P., George, S. C., & Hughes, C. C. W. (2016) · Scientific Reports · doi:10.1038/srep31589 · Cited by 387
Vascular Permeability and Drug Delivery in Cancers
Azzi, S., Hebda, J. K., & Gavard, J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00211 · Cited by 356
SyM-BBB: a microfluidic blood brain barrier model
Prabhakarpandian, B., Shen, M.-C., Nichols, J. B., Mills, I. R., Sidoryk-Wegrzynowicz, M., Aschner, M., & Pant, K. (2013) · Lab on a Chip · doi:10.1039/c2lc41208j · Cited by 339
Thorneloe, K. S., Cheung, M., Bao, W., Alsaid, H., Lenhard, S., Jian, M.-Y., Costell, M., Maniscalco-Hauk, K., Krawiec, J. A., Olzinski, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004276 · Cited by 337
Thi, M. M., Tarbell, J. M., Weinbaum, S., & Spray, D. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407474101 · Cited by 325
Alvarez, D. F., King, J. A., Weber, D., Addison, E., Liedtke, W., & Townsley, M. I. (2006) · Circulation Research · doi:10.1161/01.res.0000247065.11756.19 · Cited by 310
Willette, R. N., Bao, W., Nerurkar, S., Yue, T.-L., Doe, C. P., Stankus, G., Turner, G. H., Ju, H., Thomas, H., Fishman, C. E., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.134551 · Cited by 300
The actin cytoskeleton in endothelial cell phenotypes
Prasain, N., & Stevens, T. (2009) · Microvascular Research · doi:10.1016/j.mvr.2008.09.012 · Cited by 291
Adherens junctions connect stress fibres between adjacent endothelial cells
Millán, J., Cain, R. J., Reglero-Real, N., Bigarella, C., Marcos-Ramiro, B., Fernández-Martín, L., Correas, I., & Ridley, A. J. (2010) · BMC Biology · doi:10.1186/1741-7007-8-11 · Cited by 226
Mechanosensitive systems at the cadherin–F-actin interface
Huveneers, S., & de Rooij, J. (2013) · Journal of Cell Science · doi:10.1242/jcs.109447 · Cited by 222
Intravital analysis of vascular permeability in mice using two-photon microscopy
Egawa, G., Nakamizo, S., Natsuaki, Y., Doi, H., Miyachi, Y., & Kabashima, K. (2013) · Scientific Reports · doi:10.1038/srep01932 · Cited by 213
The TRPV4 Channel Contributes to Intercellular Junction Formation in Keratinocytes
Sokabe, T., Fukumi-Tominaga, T., Yonemura, S., Mizuno, A., & Tominaga, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.103606 · Cited by 198
Fiorio Pla, A., Ong, H. L., Cheng, K. T., Brossa, A., Bussolati, B., Lockwich, T., Paria, B., Munaron, L., & Ambudkar, I. S. (2012) · Oncogene · doi:10.1038/onc.2011.231 · Cited by 183
Goswami, C., Kuhn, J., Heppenstall, P. A., & Hucho, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011654 · Cited by 173
Veldhuis, N. A., Poole, D. P., Grace, M., McIntyre, P., & Bunnett, N. W. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009555 · Cited by 172
Self-citationMicrofluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery
Agarwal, P., Wang, H., Sun, M., Xu, J., Zhao, S., Liu, Z., Gooch, K. J., Zhao, Y., Lu, X., & He, X. (2017) · ACS Nano · doi:10.1021/acsnano.7b00824 · Cited by 168
Simulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip
Kwak, B., Ozcelikkale, A., Shin, C. S., Park, K., & Han, B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.08.027 · Cited by 165
Tumor-Vasculature-on-a-Chip for Investigating Nanoparticle Extravasation and Tumor Accumulation
Wang, H.-F., Ran, R., Liu, Y., Hui, Y., Zeng, B., Chen, D., Weitz, D. A., & Zhao, C.-X. (2018) · ACS Nano · doi:10.1021/acsnano.8b06846 · Cited by 161
Poole, D. P., Amadesi, S., Veldhuis, N. A., Abogadie, F. C., Lieu, T., Darby, W., Liedtke, W., Lew, M. J., McIntyre, P., & Bunnett, N. W. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.438184 · Cited by 159
Self-citationAdapala, R. K., Thoppil, R. J., Ghosh, K., Cappelli, H. C., Dudley, A. C., Paruchuri, S., Keshamouni, V, Klagsbrun, M., Meszaros, J. G., Chilian, W. M., et al. (2016) · Oncogene · doi:10.1038/onc.2015.83 · Cited by 153
Ryskamp, D. A., Frye, A. M., Phuong, T. T. T., Yarishkin, O., Jo, A. O., Xu, Y., Lakk, M., Iuso, A., Redmon, S. N., Ambati, B., et al. (2016) · Scientific Reports · doi:10.1038/srep30583 · Cited by 139
TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex
Lee, W. H., Choong, L. Y., Mon, N. N., Lu, S., Lin, Q., Pang, B., Yan, B., Krishna, V. S. R., Singh, H., Tan, T. Z., et al. (2016) · Scientific Reports · doi:10.1038/srep27903 · Cited by 125
Lee, W. H., Choong, L. Y., Jin, T. H., Mon, N. N., Chong, S., Liew, C. S., Putti, T., Lu, S. Y., Harteneck, C., & Lim, Y. P. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.39 · Cited by 121
Ta, H. T., Truong, N. P., Whittaker, A. K., Davis, T. P., & Peter, K. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1316262 · Cited by 105
Self-citationTang, Y., Soroush, F., Sheffield, J. B., Wang, B., Prabhakarpandian, B., & Kiani, M. F. (2017) · Scientific Reports · doi:10.1038/s41598-017-09815-9 · Cited by 102
A Microvascularized Tumor-mimetic Platform for Assessing Anti-cancer Drug Efficacy
Pradhan, S., Smith, A. M., Garson, C. J., Hassani, I., Seeto, W. J., Pant, K., Arnold, R. D., Prabhakarpandian, B., & Lipke, E. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-21075-9 · Cited by 96
Wu, S., Jian, M.-Y., Xu, Y.-C., Zhou, C., Al-Mehdi, A.-B., Liedtke, W., Shin, H.-S., & Townsley, M. I. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00015.2009 · Cited by 94
Phuong, T. T. T., Redmon, S. N., Yarishkin, O., Winter, J. M., Li, D. Y., & Križaj, D. (2017) · The Journal of Physiology · doi:10.1113/jp275052 · Cited by 91
Shear stress mediates exocytosis of functional TRPV4 channels in endothelial cells
Baratchi, S., Almazi, J. G., Darby, W. G., Tovar-Lopez, F. J., Mitchell, A., & McIntyre, P. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2018-8 · Cited by 90
Microfluidic devices for modeling cell–cell and particle–cell interactions in the microvasculature
Prabhakarpandian, B., Shen, M.-C., Pant, K., & Kiani, M. F. (2011) · Microvascular Research · doi:10.1016/j.mvr.2011.06.013 · Cited by 89
Kluger, M. S., Clark, P. R., Tellides, G., Gerke, V., & Pober, J. S. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300893 · Cited by 87
Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells
Peters, A. A., Jamaludin, S. Y. N., Yapa, K. T. D. S., Chalmers, S., Wiegmans, A. P., Lim, H. F., Milevskiy, M. J. G., Azimi, I., Davis, F. M., Northwood, K. S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.234 · Cited by 85
Fernández‐Martín, L., Marcos‐Ramiro, B., Bigarella, C. L., Graupera, M., Cain, R. J., Reglero-Real, N., Jiménez-Reinoso, A., Cernuda‐Morollón, E., Correas, I., Cox, S., et al. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.252080 · Cited by 82
Toward the broad adoption of 3D tumor models in the cancer drug pipeline
Cox, M. C., Reese, L. M., Bickford, L. R., & Verbridge, S. S. (2015) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00172 · Cited by 80
Khor, S. Y., Vu, M. N., Pilkington, E. H., Johnston, A. P. R., Whittaker, M. R., Quinn, J. F., Truong, N. P., & Davis, T. P. (2018) · Small · doi:10.1002/smll.201801702 · Cited by 80
Self-citationHuang, K., Boerhan, R., Liu, C., & Jiang, G. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00726 · Cited by 74
Synthetic Microvascular Networks for Quantitative Analysis of Particle Adhesion
Prabhakarpandian, B., Pant, K., Scott, R. C., Patillo, C. B., Irimia, D., Kiani, M. F., & Sundaram, S. (2008) · Biomedical Microdevices · doi:10.1007/s10544-008-9170-y · Cited by 68
Shin, S. H., Lee, E. J., Hyun, S., Chun, J., Kim, Y., & Kang, S. S. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2011.11.002 · Cited by 63
TRPV4 channel activation selectively inhibits tumor endothelial cell proliferation
Thoppil, R. J., Adapala, R. K., Cappelli, H. C., Kondeti, V., Dudley, A. C., Gary Meszaros, J., Paruchuri, S., & Thodeti, C. K. (2015) · Scientific Reports · doi:10.1038/srep14257 · Cited by 63
Synthetic tumor networks for screening drug delivery systems
Prabhakarpandian, B., Shen, M.-C., Nichols, J. B., Garson, C. J., Mills, I. R., Matar, M. M., Fewell, J. G., & Pant, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.018 · Cited by 57
Matsumoto, K., Yamaba, R., Inoue, K., Utsumi, D., Tsukahara, T., Amagase, K., Tominaga, M., & Kato, S. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14072 · Cited by 57
Aragon-Sanabria, V., Pohler, S. E., Eswar, V. J., Bierowski, M., Gomez, E. W., & Dong, C. (2017) · Scientific Reports · doi:10.1038/srep45835 · Cited by 55
Cappelli, H. C., Kanugula, A. K., Adapala, R. K., Amin, V., Sharma, P., Midha, P., Paruchuri, S., & Thodeti, C. K. (2019) · Cancer Letters · doi:10.1016/j.canlet.2018.07.042 · Cited by 54
Pink, D., Schulte, W., Parseghian, M. H., Zijlstra, A., & Lewis, J. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033760 · Cited by 48
Reply to “Evaluation of nanomedicines: stick to the basics”
Wilhelm, S., Tavares, A. J., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.74 · Cited by 43
Adhesion patterns in the microvasculature are dependent on bifurcation angle
Lamberti, G., Soroush, F., Smith, A. M., Kiani, M. F., Prabhakarpandian, B., & Pant, K. (2015) · Microvascular Research · doi:10.1016/j.mvr.2015.02.004 · Cited by 39
Bifurcations: Focal Points of Particle Adhesion in Microvascular Networks
Prabhakarpandian, B., Wang, Y., Rea-Ramsey, A., Sundaram, S., Kiani, M. F., & Pant, K. (2011) · Microcirculation · doi:10.1111/j.1549-8719.2011.00099.x · Cited by 38
Moy, A. B., Blackwell, K., Wang, N., Haxhinasto, K., Kasiske, M. K., Bodmer, J. E., Reyes, G., & English, A. E. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00292.2003 · Cited by 33
Zamarripa, D. A., Noguez-Imm, R., Cortés, A. M. B., Ruíz, O. V., Bernardini, M., Fiorio, A., Gkika, D., Prevarskaya, N. B., López‐Casillas, F., Liedtke, W., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13621-8 · Cited by 33
Janssen, D. A. W., Jansen, C. J. F., Hafmans, T. G., Verhaegh, G. W., Hoenderop, J. G., Heesakkers, J. P. F. A., & Schalken, J. A. (2016) · Acta Physiologica · doi:10.1111/apha.12701 · Cited by 28
Cited by
Xu, M., Qi, Y., Liu, G., Song, Y., Jiang, X., & Du, B. (2023) · ACS Nano · doi:10.1021/acsnano.3c05853 · Cited by 632
Microfluidic Devices: A Tool for Nanoparticle Synthesis and Performance Evaluation
Gimondi, S., Ferreira, H., Reis, R. L., & Neves, N. M. (2023) · ACS Nano · doi:10.1021/acsnano.3c01117 · Cited by 376
Mechanical Stimulation: A Crucial Element of Organ-on-Chip Models
Thompson, C. L., Fu, S., Heywood, H. K., Knight, M. M., & Thorpe, S. D. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.602646 · Cited by 178
Organ-on-a-chip platforms for accelerating the evaluation of nanomedicine
Chen, X., Zhang, Y. S., Zhang, X., & Liu, C. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.09.022 · Cited by 107
“interaction between nanomedicine and tumor cells [46,100,105].”
BackgroundHow Advancing are Mesoporous Silica Nanoparticles? A Comprehensive Review of the Literature
Porrang, S., Davaran, S., Rahemi, N., Allahyari, S., & Mostafavi, E. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s353349 · Cited by 114
“Some additive features of these nanoparticles include: extravasating across tumor vascular walls, penetration of the tumor interstitium, targetability with the use of surface receptors on cancer cells, and controlling the release of the anticancer drug locally.(93,94) The development of nanocarriers has been influence…”
Background
Metadata
- Authors
- Vu, M. N., Rajasekhar, P., Poole, D. P., Khor, S. Y., Truong, N. P., Nowell, C. J., Quinn, J. F., Whittaker, M., Veldhuis, N. A., & Davis, T. P.
- Affiliations
- Hanoi University of Pharmacy (VN)
- Australian Research Council (AU)
- Monash University (AU)
- University of Warwick (GB)
- Corresponding author
- Veldhuis, Nicholas A.
- Davis, Thomas P.
- ORCID
- Venue
- ACS Applied Nano Materials
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-03-29
- Volume
- 2
- Issue
- 4
- Pages
- 1844-1856
- ISSN
- 2574-0970 (ISSN-L)
- OpenAlex
- W2927037977
- Cited by
- 52
- References
- 72
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 8 · 2023: 9 · 2022: 11 · 2021: 9 · 2020: 6 · 2019: 1
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- ACS Applied Nano Materials (publishedVersion, other-oa)
- Monash University Research Portal (Monash University) (submittedVersion, other-oa)
- Warwick Research Archive Portal (University of Warwick) (submittedVersion)
- Funders
- Takeda Pharmaceuticals U.S.A. (NA)
- Australian Research Council (DE180100076, FL140100052)
- Department of Education and Training (NA)
- Centre of Excellence in Convergent Bio-Nano Science and Technology, Australian Research Council (CE140100036)
- Faculty of Pharmacy and Pharmaceutical Sciences, Monash University (NA)
- Government of Vietnam (NA)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- nanoparticle extravasation, tumor-on-a-chip, microfluidic tumor model, enhanced permeability and retention effect, adherens junctions, actin cytoskeleton, tumor microenvironment, nanoparticle surface chemistry, nanoparticle size, tumor accumulation, edema, targeted cancer drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.